You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

561 Results
Drug
Other Name(s): Erleada®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
May 2019
Guidelines and Advice
Guidelines and Advice
Status: In-Review
ID: RR 21-5
Version: n/a
Jan 2019
Regimen
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Jun 2025
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2025
Guidelines and Advice
Mar 2019
Guidelines and Advice

Pages